MX2023015398A - Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina. - Google Patents

Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina.

Info

Publication number
MX2023015398A
MX2023015398A MX2023015398A MX2023015398A MX2023015398A MX 2023015398 A MX2023015398 A MX 2023015398A MX 2023015398 A MX2023015398 A MX 2023015398A MX 2023015398 A MX2023015398 A MX 2023015398A MX 2023015398 A MX2023015398 A MX 2023015398A
Authority
MX
Mexico
Prior art keywords
treatment
compositions
antitrypsin deficiency
antitrypsin
deficiency
Prior art date
Application number
MX2023015398A
Other languages
English (en)
Spanish (es)
Inventor
Nigel Ramsden
David John Fox
James Andrew Huntington
Original Assignee
Centessa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals Uk Ltd filed Critical Centessa Pharmaceuticals Uk Ltd
Publication of MX2023015398A publication Critical patent/MX2023015398A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023015398A 2021-06-15 2022-06-15 Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina. MX2023015398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108523.8A GB202108523D0 (en) 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency
PCT/GB2022/051502 WO2022263816A1 (en) 2021-06-15 2022-06-15 COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
MX2023015398A true MX2023015398A (es) 2024-04-29

Family

ID=76954605

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015398A MX2023015398A (es) 2021-06-15 2022-06-15 Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina.

Country Status (12)

Country Link
US (1) US20240197707A1 (https=)
EP (1) EP4355328A1 (https=)
JP (1) JP7854001B2 (https=)
KR (1) KR20240027693A (https=)
CN (1) CN117794538A (https=)
AU (1) AU2022295130A1 (https=)
BR (1) BR112023026510A2 (https=)
CA (1) CA3223130A1 (https=)
GB (1) GB202108523D0 (https=)
IL (1) IL309355A (https=)
MX (1) MX2023015398A (https=)
WO (1) WO2022263816A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
US8258158B2 (en) 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2012097371A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
MX2020013853A (es) 2018-06-22 2021-05-27 Ucl Business Ltd Compuestos innovadores.
CA3114672A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201918410D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Also Published As

Publication number Publication date
JP7854001B2 (ja) 2026-04-30
CN117794538A (zh) 2024-03-29
JP2024523406A (ja) 2024-06-28
EP4355328A1 (en) 2024-04-24
WO2022263816A1 (en) 2022-12-22
IL309355A (en) 2024-02-01
GB202108523D0 (en) 2021-07-28
US20240197707A1 (en) 2024-06-20
KR20240027693A (ko) 2024-03-04
CA3223130A1 (en) 2022-12-22
BR112023026510A2 (pt) 2024-03-05
AU2022295130A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
ECSP21051825A (es) COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
MX2024005304A (es) Derivado del acido fenilpropionico sustituido y uso del mismo.
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JOP20250051A1 (ar) مُعدِّلات مضاد تربسين ألفا-1
PY22104936A (es) "inhibidores y/o degradadores de bckdk"
BR112022013547A2 (pt) Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição
MX2023015398A (es) Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina.
UY30585A1 (es) Derivados de isoserina como inhibidores del factor ixa de la coagulacion
MX2022007174A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
BR112022011566A2 (pt) Compostos e uso dos mesmos para o tratamento de deficiência de a1-antitripsina